Positive - HUTCHMED's savolitinib shows promising results in lung cancer trials with TAGRISSO

From Nasdaq: 2025-03-19 23:33:42

HUTCHMED (China) Limited announced positive results from the SAVANNAH Phase II trial, showing high and durable response rates with the combination of savolitinib and TAGRISSO in MET-high lung cancer. Long-term survival benefits and safety were observed in the savolitinib Phase IIIb study for METex14 non-small cell lung cancer. Savolitinib plus TAGRISSO demonstrated a confirmed 56% ORR, 7.1-9.9 months DoR, and 7.4-7.5 months PFS. Safety results were consistent with established profiles. Savolitinib is jointly developed by AstraZeneca and HUTCHMED, receiving Fast Track Designation from the FDA in 2023. In China, savolitinib demonstrated survival benefits in MET exon 14 skipping alteration NSCLC patients. Surufatinib plus immunotherapy as maintenance therapy showed durable survival benefits for extensive-stage small cell lung cancer patients.



Read more at Nasdaq: HUTCHMED Highlights Savolitinib SAVANNAH Phase II Results And Additional Key Data